{
  "id": 1844526,
  "title": "LG Chem Begins Preclinical Development of Genuv’s Next-Generation Immuno-Oncology Candidate",
  "url": "https://urgent.news/2026/08/19/lg-chem-begins-preclinical-development-of-genuvs-next-generation",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-19T01:52:50.000Z",
  "source": {
    "name": "Korea IT Times",
    "slug": "korea-it-times",
    "url": "https://www.koreaittimes.com/news/articleView.html?idxno=156242"
  },
  "original_language": "en",
  "account": "LG Chem, the South Korean chemical company, has commenced preclinical studies for GNV205, a next-generation immuno-oncology candidate licensed from Genuv, a Korean biotech firm. This strategic move is aimed at bolstering LG Chem's arsenal of innovative cancer therapies. Preclinical studies are being conducted on GNV205 in solid tumors to gauge its therapeutic potential and development feasibility.\n\nGNV205 is an antibody-cytokine fusion protein, a novel combination of a PD-1 antibody, which inhibits immune-suppressing signals, and interleukin-2 (IL-2), a cytokine that boosts immune cells. The unique design of GNV205 enables it to become more active in the acidic tumor microenvironment, thus concentrating IL-2 activity around cancer tissue while minimizing systemic toxicity. This strategy aims to boost the immune response against tumors while mitigating a major drawback of traditional IL-2 therapies, which often cause substantial toxicity when administered throughout the body.\n\nLG Chem's interest in GNV205 is driven by its potential as a treatment for patients who have had limited success with existing immunotherapies or have developed resistance to treatment. This development underscores LG Chem's approach of merging internal research and development (R&D) with external technology acquisition.\n\nThe rights to GNV205 were acquired exclusively from Genuv by LG Chem in September 2025. Under the agreement, LG Chem paid an upfront fee and will make additional milestone and royalty payments contingent on the drug's development and commercial success. Genuv, established in 2016, is a biotech company focusing on drug development for cancer and central nervous system disorders using its proprietary drug discovery platforms.\n\nFor LG Chem, this partnership offers the chance to integrate a locally developed biotech asset into its global R&D pipeline, thereby expanding its presence in the competitive immuno-oncology market. The company further diversifies its oncology portfolio through external collaborations, including a recent partnership with China-based OTR Therapeutics.\n\nLG Chem's CEO, Son Ji-woong, emphasized the company's commitment to expanding its oncology pipeline by blending internal R&D with the introduction of innovative technologies from external partners. This highlights LG Chem's dedication to both proprietary research and external innovation to identify and develop new oncology candidates.",
  "summary": "LG Chem is moving ahead with the development of GNV205, a next-generation immuno-oncology candidate licensed from South Korean biotech company Genuv, as it seeks to strengthen its pipeline of innovative cancer therapies.The company said Aug. 19 that it has begun preclinical studies of GNV205 in soli",
  "key_points": [
    "LG Chem starts preclinical studies for GNV205, a next-gen immuno-oncology drug.",
    "GNV205 combines PD-1 antibody with interleukin-2 for targeted immune response.",
    "LG Chem acquired exclusive rights to GNV205 in September 2025."
  ],
  "editors_take": "LG Chem's development of GNV205 signifies a strategic expansion of its immuno-oncology portfolio, potentially offering a treatment option for patients resistant to existing therapies and bolstering its global R&D pipeline.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}